MedPageToday -- When given in doses based on weight, an investigational prodrug of ribavirin had efficacy comparable to ribavirin in chronic hepatitis C but with less hemolytic anemia, researchers reported.
MedPageToday -- When given in doses based on weight, an investigational prodrug of ribavirin had efficacy comparable to ribavirin in chronic hepatitis C but with less hemolytic anemia, researchers reported.